SOURCE: CellaVision AB

August 27, 2009 03:03 ET

CellaVision evaluates new product for the veterinary market

LUND, SWEDEN--(Marketwire - August 27, 2009) - CellaVision, which develops and sells digital morphology products for the routine analysis of blood and other body fluids, is adapting its current range of products for use in veterinary laboratories. Several veterinary laboratories are evaluating CellaVision's products in Sweden and the US. The results are expected before the end of the year 2009.

"The veterinary market is showing interest in our concept and our products for quicker and more standardized analytical results, which may open up an entirely new market for our hematology products," says Yvonne Mårtensson, CEO of CellaVision. "A number of Swedish veterinary hospitals have evaluated our product with positive outcomes. However, we will wait to decide on when to launch our product until the US market has made an evaluation. We are expecting results to come in by the end of the year."

Veterinary laboratories can use the CellaVision analyzers to assess blood cells as well as create digital images of slide areas, so-called Digital Slides. Blood analysis is an important part of diagnosing a number of diseases, including different types of infections and blood diseases. The benefits of using CellaVision's products are the same as when using them on human blood, namely quicker and more standardized results, digital archiving of results in patient journals, as well as the transfer of digital images to experts outside the laboratory.

One of the clinical studies was performed at the veterinary laboratory at the Swedish University of Agricultural Sciences (SLU) in Uppsala. The response was positive:

"Being able to make fast and correct diagnoses is of the essence for veterinarians," says Inger Lilliehöök, veterinarian at SLU. "By using CellaVision's technology, veterinary hospitals can improve the quality of analytical results and increase the ability to diagnose. In that way, pets can be offered the appropriate care."

In general, there is potential for medical technology products in the veterinary market. In Sweden there are four regional veterinary hospitals, 24 medium-sized hospitals, and a number of small animal clinics. One in four Swedish households owns a pet, accounting for the 1.5 million cats and 950 000 dogs in the country. In the US there are around 3000 veterinary hospitals with its own laboratory and 50 large-sized commercial veterinary laboratories. More than one third of the American households own a pet. The number of cats is approximately 90 million and dogs 73 million.

For more information, please contact:
Yvonne Mårtensson, CEO, CellaVision AB
Phone: +46 46 286 44 01. E-mail:

About CellaVision

CellaVision AB develops, markets, and sells market leading image analysis based systems for routine analysis of blood and other body fluids. The company has a core competence in development of software and hardware for automatic image analysis of cells and cell changes for applications in health and medical care. The company develops and markets systems for automatic differentials of white blood cells and red morphology, and software for education and quality assurance of differentials. The company's associates have expertise in advanced imaging analysis, artificial intelligence, and automated microscopy.

The company headquarters are in Lund, Sweden. The company also has subsidiaries in Florida, USA, Toronto, Canada and Yokohama, Japan. For more information, visit

CellaVision's share is listed on First North Premier at the OMX Stockholm Stock Exchange. The company's Certified Advisor is Remium AB.

This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.

Copyright © Hugin AS 2009. All rights reserved.

Contact Information